As cases of CD are rising in Brazil, we designed an Early Access Program (EAP) to provide easy access to ustekinumab for patients with moderate-to-severe CD refractory or intolerant to conventional treatment and anti-TNF α therapy, and in urgent need of treatment. This evidence concerns the gene TNF and Cowden disease.